London, UK, 3rd February 2015: MRC Technology (MRCT) has appointed Dr Edward Bliss in the new role of General Counsel and Company Secretary. Edward will join MRCT on 16 March from Shire Pharmaceuticals plc, where he is currently Legal Director. Prior to that he was the General Counsel and Company Secretary at Ark Therapeutics Group plc and he joined Ark from private practice with the international life sciences law firm Covington and Burling LLP.
A solicitor, Edward also holds a degree in Physiology and PhD in Neuroscience and brings a wealth of experience to the role. His responsibilities will include licensing, governance, compliance, and in-house legal affairs.
Welcoming Edward, Dave Tapolczay, Chief Executive Officer, MRC Technology said: “Ed will be a great asset and we look forward to him joining. Licensing is a key part of our mission to drive scientific research to benefit patients. We have already negotiated over 400 commercial licences and Ed will continue to build on this success.”
Dr Edward Bliss said: “It is a tremendous privilege to be joining MRC Technology and I look forward to working with Dave Tapolczay and his team in their important goal of progressing the further development of innovative medical research.”
Media enquiries
Sarah Jeffery
Zyme Communications
E-mail: sarah.jeffery@zymecommunications.com
Phone: +44 (0) 7771 730919
At MRC Technology
Liezel Tipper
PR and Communications Manager
E-mail: liezel.tipper@tech.mrc.ac.uk
Phone: +44 (0)20 7391 2772
About MRC Technology
MRC Technology (www.mrctechnology.org) is an independent life science medical research charity, offering professional services to organisations within the academic, charity, biotechnology and pharmaceutical sectors globally. Services include IP management and research and development for diagnostics, small molecules and therapeutic antibodies. MRC Technology bridges the gap between basic medical research and commercialisation, helping early discoveries progress to clinical application. Four of MRC Technology’s projects have led to approved drugs (Tysabri®, Actemera®, Entyvio®, Keytruda®) and the company has a strong pipeline in development.
Please note MRC Technology has been independent from the UK’s Medical Research Council (MRC) since 2000.
Help employers find you! Check out all the jobs and post your resume.
